Browse the evidence

Genetically proxied activation of the glucagon-like peptide-1 receptor (GLP1RA) is causally associated with a reduced risk of schizophrenia.

This study suggests that medications activating the GLP-1 receptor (like semaglutide or liraglutide) may lower the risk of developing schizophrenia, primarily through their effect on body weight. For individuals at high risk of schizophrenia who are overweight, using these medications for weight management might offer a dual benefit of metabolic health and reduced psychiatric risk. However, this is based on genetic data, not direct clinical trials, so it should not replace standard psychiatric care.

Non-sulfated CCK peptides stimulate gastric acid secretion via CCK2 receptors, acting similarly to gastrin, whereas sulfated CCK inhibits acid secretion via CCK1 receptors.

The form of CCK matters. In rare tumors (CCKoma), non-sulfated CCK can cause ulcers by stimulating acid. In healthy individuals, sulfated CCK inhibits acid. This distinction is crucial for understanding gastric pathologies.

Higher genetically predicted BMI does not increase the risk of cancer mortality.

While higher BMI increases risks for other causes of death, this study did not find a link to cancer mortality.

Twelve weeks of dapiglutide (4 mg or 6 mg) once weekly does not produce a statistically significant reduction in body weight compared to placebo in adults with obesity.

In this study, taking 4 mg or 6 mg of dapiglutide once weekly for 12 weeks did not lead to significant weight loss compared to a placebo in people with obesity. The drug was safe, but the dose might be too low or the treatment period too short to see results. Future studies may need higher doses or longer durations.

Emergency department exposures to GLP-1 and GLP-1/GIP receptor agonists predominantly result in mild, self-limiting gastrointestinal symptoms (nausea, vomiting) that typically resolve within 8 to 24 hours with supportive care.

If you or someone else takes too much of a GLP-1 medication (like Ozempic or Wegovy), expect nausea and vomiting. These symptoms are usually mild and go away within a day. Focus on hydration and rest. Seek medical help if you feel faint, have severe abdominal pain, or cannot keep fluids down.

YouTube videos on semaglutide (Ozempic/Wegovy) largely fail to adequately communicate critical safety risks, specifically the risk of aspiration during anesthesia, the persistence of side effects due to the drug's long half-life, the risk of counterfeit drugs, and the lack of long-term data.

Do not rely on YouTube videos for safety information about semaglutide. They often miss critical risks like aspiration during surgery, the persistence of side effects due to the drug's long half-life, and the danger of counterfeit products. Always consult a physician for personalized advice and safety monitoring.